Clinical Trial

Safety and Efficacy of APG-157 in Head and Neck Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-03-28; most recent amendment 2026-01-14.
Status change: Recruiting → Active, Not Recruiting 2026-01-14
Status change: Not Yet Recruiting → Recruiting 2022-04-22
Trial Details
NCT Number NCT05312710
Lead Sponsor Aveta Biomics, Inc.
Conditions Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Enrollment 24 participants
Start Date 2022-04-22
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-16